Innovating Works

RGD-Diabetes

Financiado
Development of RGD therapeutics for cardio metabolic disease
In Europe, 58 million people are living with type 2 diabetes and 36 million people are at risk of developing the condition. Macrovascular disease is the commonest cause of morbidity and mortality in type 2 diabetes, yet current di... In Europe, 58 million people are living with type 2 diabetes and 36 million people are at risk of developing the condition. Macrovascular disease is the commonest cause of morbidity and mortality in type 2 diabetes, yet current diabetes therapies have failed to consistently reduce cardiovascular events. In my Starting Grant, I discovered that a circulating protein, IGF binding protein-1, possesses several favourable characteristics– including insulin sensitisation, amelioration of glucose intolerance, blood pressure lowering, reduced atherosclerosis and increased vascular repair. These effects are mediated by interaction of the protein’s RGD-domain with cell-surface α5β1 integrin receptors, which increases insulin-stimulated glucose uptake in skeletal muscle cells and glucose-stimulated insulin secretion in pancreatic islets. Hence the ‘idea’ from my Starting Grant is that RGD-integrin interaction could be exploited therapeutically in diabetes. In this Proof-of-Concept grant, we will take the first step towards commercialisation of the idea by designing and testing small molecule mimics of the RGD domain of IGFBP1 as diabetes therapeutics. Using in silico modelling based on the known structures of IGFBP1 and the α5β1 integrin ectodomain, we will design a small molecule library of commercially available potential agonists. We will carry out virtual high throughput screening of the library for molecules matching the shape and electrostatic potential of the RGD domain of IGFBP1 as predicted to bind to α5β1 integrin. As contingency, we will also identify in silico ‘me-too’ analogues of known integrin ligands. We will test the best quality hits through ADME profiling and validate therapeutic activity in vitro and in vivo. At the end of the project, we anticipate we will have identified small molecule RGD mimics which can subsequently be progressed through the drug-discovery pipeline through translation grant funding or pharmaceutical industry Open Innovation schemes. ver más
30/11/2021
UNIVLEEDS
150K€
Duración del proyecto: 32 meses Fecha Inicio: 2019-03-27
Fecha Fin: 2021-11-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2021-11-30
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-2018-PoC: ERC Proof of Concept Grant
Cerrada hace 6 años
Presupuesto El presupuesto total del proyecto asciende a 150K€
Líder del proyecto
UNIVERSITY OF LEEDS No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5